News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Gilead Sciences, Inc. Profit Rises a Higher-than-Expected 21 Percent
April 21, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters - Gilead Sciences Inc (GILD.O) said on Tuesday first-quarter profit rose 21 percent, topping analysts' expectations, on increased sales of its drugs to treat the virus that causes AIDS.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Gilead Sciences, Inc.
MORE ON THIS TOPIC
China
AstraZeneca taps China’s CSPC again, betting up to $1.77B to target kidney diseases
July 2, 2026
·
2 min read
·
Tristan Manalac
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
·
2 min read
·
Gabrielle Masson
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
